179 related articles for article (PubMed ID: 14529395)
1. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors.
Gould WR; Leadley RJ
Curr Pharm Des; 2003; 9(28):2337-47. PubMed ID: 14529395
[TBL] [Abstract][Full Text] [Related]
2. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents.
Leadley RJ; Chi L; Rebello SS; Gagnon A
J Pharmacol Toxicol Methods; 2000; 43(2):101-16. PubMed ID: 11150738
[TBL] [Abstract][Full Text] [Related]
3. Coagulation factor Xa inhibition: biological background and rationale.
Leadley RJ
Curr Top Med Chem; 2001 Jun; 1(2):151-9. PubMed ID: 11899250
[TBL] [Abstract][Full Text] [Related]
4. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
5. Role of current and emerging antithrombotics in thrombosis and cancer.
Mousa SA
Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
[TBL] [Abstract][Full Text] [Related]
6. Advances in antithrombotic agents.
Chakrabarti R; Das SK
Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):175-85. PubMed ID: 17630943
[TBL] [Abstract][Full Text] [Related]
7. Thrombin inhibitors and anti-factor Xa agents in the treatment of arterial occlusion.
Klauss V; Spannagl M
Curr Drug Targets; 2006 Oct; 7(10):1285-90. PubMed ID: 17073589
[TBL] [Abstract][Full Text] [Related]
8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
9. Novel antithrombotic strategies in cardiovascular diseases.
Golino P; Loffredo F; Riegler L; Renzullo E; Cocchia R
Curr Opin Investig Drugs; 2005 Mar; 6(3):298-306. PubMed ID: 15816507
[TBL] [Abstract][Full Text] [Related]
10. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
11. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.
Ten Cate H; Guzik TJ; Eikelboom J; Spronk HMH
Cardiovasc Res; 2021 Jul; 117(9):2030-2044. PubMed ID: 32931586
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
15. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
Lee YK; Player MR
Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
[TBL] [Abstract][Full Text] [Related]
16. Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors.
Hao X; Zuo X; Kang D; Zhang J; Song Y; Liu X; Zhan P
Expert Opin Drug Discov; 2019 Sep; 14(9):915-931. PubMed ID: 31172842
[No Abstract] [Full Text] [Related]
17. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
18. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.
Masters JJ; Franciskovich JB; Tinsley JM; Campbell C; Campbell JB; Craft TJ; Froelich LL; Gifford-Moore DS; Hay LA; Herron DK; Klimkowski VJ; Kurz KD; Metz JT; Ratz AM; Shuman RT; Smith GF; Smith T; Towner RD; Wiley MR; Wilson A; Yee YK
J Med Chem; 2000 Jun; 43(11):2087-92. PubMed ID: 10841787
[No Abstract] [Full Text] [Related]
19. Current evidence for antithrombotic therapy after peripheral vascular interventions.
Saha SP; Whayne TF; Mukherjee D
Curr Vasc Pharmacol; 2013 Jul; 11(4):507-13. PubMed ID: 22272907
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
